Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 13S-19S

  Kessler, Robert E ^a,b   Fung Tomc, Joan ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; CITROBACTER FREUNDII; CLINICAL TRIAL; CONFERENCE PAPER; DRUG POTENCY; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; STATISTICS; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 0030600120     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00103-9     Document Type: Conference Paper

References (38)

1. Bodey, GP, Ho DH, LeBlanc B. In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:265-269.
2. Clarke AM, Zemcov SJV, Wright JM. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other β-lactam antibiotics. J Antimicrob Chemother. 1985;15:305-310.
3. Fuchs PC, Jones RN, Barry AL, Ayers LW, Gavan TL, Gerlach EH. In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates. Diagn Microbiol Infect Dis. 1986;5:345-349.
4. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:679-682.
5. Kessler RE, Bies M, Buck RE, et al. Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum β-lactam antibiotics. Antimicrob Agents Chemother. 1985;27:207-216.
6. Moody J-A, Peterson LR, Gerding DN. Comparative in vitro activity of BMY-28142 alone and in combination with amikacin against clinical strains of Pseudomonas aeruginosa, Staphylococcus aureus and Enterobacteriaceae. Curr Therap Res. 1986;39:230-238.
7. Neu HC, Chin N-X, Jules K, Labthavikul P. The activity of BMY-28142, a new broad spectrum β-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17:441-452.
8. Neu HC, Chin N-X, Novelli A. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1988;32:1666-1675.
9. Steele JCH Jr, Edwards BH, Rissing JP. In-vitro activity of BMY-28142, a new aminothiazolyl cephalosporin. J Antimicrob Chemother. 1985;16:463-468.
10. Tomatsu K, Ando S, Masuyoshi S, Hirano M, Miyaki T, Kawaguchi H. Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin. J Antibiot. 1986;39:1584-1591.
11. Tsuji A, Maniatis A, Bertram MA, Young LS. In vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents. Antimicrob Agents Chemother. 1985;27:515-519.
12. Van Landuyt HW, Lambert A, Boelaert J, Gordts B. In vitro activity of BRL 36650, a new penicillin. Antimicrob Agents Chemother. 1986;29:362-366.
13. Visser MR, Hoepelman IM, Beumer H, Rozenberg-Arska M, Vernoef J. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338). Eur J Clin Microbiol Infect Dis. 1989;8:1061-1064.
14. Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Agents Chemotber. 1989;33:498-502.
15. Knapp CC, Washington JA. Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa depressed for class I β-lactamase. J Antimicrob Chemother. 1989;24:1011-1012.
16. Neu HC, Chin N-X. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance. Chemioterapia. 1985;4:63-70.
17. Sanders CC, Sanders WE Jr. Microbial resistance to newer generation β-lactam antibiotics: clinical and laboratory implications. J Infect Dis. 1985;151:399-406.
18. Sanders CC, Sanders WE Jr. Type I β-lactamases of gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis. 1986; 154:792-800.
19. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990;34:337-342.
20. Bellido F, Pechère J-C, Hancock REW. Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother. 1991;35:73-78.
21. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for β-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother. 1986;29:845-848.
22. Then RL, Angehrn P. Ways to overcome cephalosporinase-mediated β-lactam resistance in Enterobacter cloacae. Chemioterapia. 1985;4:83-89.
23. Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome and cefaclidine binding affinities for pencillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991;35:2312-2317.
24. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn Microbiol Infect Dis. 1994;19:33-38.
25. Toye BW, Scriver SR, Low DE, and The Canadian Antimicrobial Resistance Study Group. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 1993;32(suppl B):81-86.
26. Yee YC, Thornsberry C, Brown SD, et al. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32:13-19.
27. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994;38:898-900.
28. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993;32:87-94.
29. Pechère J-C, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 1992;29:563-573.
30. Fung-Tomc J, Huczko E, Pearce M, Kessler R. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftadime, and cefotaxime. Antimicrob Agents Chemother. 1988;32:1443-1445.
31. Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefepime in vitro. Chemotherapy. 1994;40:384-390.
32. Thornsberry C, Brown SD, Yee YC, et al. In vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32.
33. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Approved standard. Villanova, PA: NCCLS; 1990. Document M7-A2.
34. Cunha BA, Gill MV. Cefepime. Med Clin North Am. 1995;79:721-732.
35. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Cefepime: a new fourth-generation cephalosporin. Am J Hosp Pharm. 1994;51:463-477.
36. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47:471-505.
37. Nikaido H, Normark S. Sensitivity of Escherichia coli to various β-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic β-lactamases: a quantitative predictive treatment. Mol Microbiol. 1987;1:29-36.
38. Dyke JW, Angones D, Bhakta D, Tenjarla G, Kumar A. Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital. Chemotherapy. 1993;39:315-321.